These Analysts Slash Their Forecasts On Insulet After Q2 Results

Insulet Corp. (NASDAQ: PODD ) on Wednesday posted upbeat second-quarter results but lowered its full-year revenue guidance.

Adjusted earnings rose to $1.66 per share from $1.17 a year earlier, beating the analyst consensus estimate of $1.45.

Revenue increased 23.5% year over year to $801.7 million, topping the Street estimate of $787.2 million. "We delivered another quarter of broad-based growth, robust margin expansion, and positive free cash flow," CEO Ashley McEvoy said.

For the third quarter, Insulet expects revenue of approximately $829.9 million to $844.0 million, below the analyst consensus estimate of $845.5 million.

The company also lowered its full-year 2026 revenue outlook to a range of approximately $3.25 billion to $3.30 billion from its prior forecast of $3.28 billion to $3.33 billion.

The revised guidance also came in below the Wall Street estimate of $3.32 billion.

Insulet shares fell 1.4% to $131.37 in pre-market trading.

These analysts made changes to their price targets on Insulet following earnings announcement.

Truist Securities analyst Richard Newitter downgraded the stock from Buy to Hold and lowered the price target from $210 to $153.

JP Morgan analyst Robbie Marcus downgraded the stock from Overweight to Neutral and cut the price target from $275 to $152.

Wells Fargo analyst Lawrence Biegelsen downgraded the stock from Overweight to Equal-Weight and slashed the price target from $255 to $144.

BTIG analyst Marie Thibault downgraded the stock from Buy to Neutral.

Considering buying PODD stock? Here’s what analysts think: Photo via Shutterstock